The methods proposed for the detection of cancer driver mutations are based on the estimation of background mutation rate, impact on protein function, or network influence.
Introduction and the probability of associations of between mutated genes and cancer survival time, which may help the discovery of novel genes, mutations, and provide important insights to cancer biology.
Here we propose VALORATE (Velocity and Accuracy for the LOg RAnk TEst), a novel algorithm, which quickly provides a precise and accurate estimation of the empirical null distribution and the probability value of the Log-Rank statistic being zero regardless of the population size and the fraction of mutations. We first validate the accuracy and velocity of VALORATE in simulated and cancer data. Then, we apply VALORATE to analyze the gene mutations associated with survival times in 61 cancer datasets including more than 40 cancer types from TCGA and ICGC, which cover 11,655 and 2,779 cancer samples respectively. We note that, regardless of the method, the significance can be influenced by hypermutated samples. Next, we show comparisons of the estimations of VALORATE and the ALRT suggesting that the ALRT may detect many false positives and false negatives genes. As a consequence of these differences, we observe that the proportions of genes associated with low-and high-risk groups are largely different. We find that genes associated with survival using VALORATE were mostly cancer-type specific. From the identified genes, many are well-known cancer genes but many others are novel associations. These results seem to be reliable because significant genes appear to be expressed in the mutated tissues and its mutations have high functional impacts. We conclude that VALORATE is a valuable tool for cancer genomics and may be useful for other statistical applications.
Results

Validation of the VALORATE algorithm
The VALORATE algorithm shown in Figure 1 (see details in Materials and Methods) is based on the postulate that the log-rank distribution L will be highly dependent on k, the number of cooccurrences of events and mutations when the number of subjects in one group is very low or presumably when there is a highly unbalanced number of subjects between groups. Thus, L is a weighted sum of conditional distributions L k . The procedure is fast to compute because L k can be estimated by sampling.
To show the accuracy of VALORATE in the estimation of the log-rank distribution, we used simulations comparing the exact distribution of all possible combinations of the log-rank statistic with the distribution estimated by VALORATE. A representative simulation shown in Figure 2A suggests that VALORATE can accurately estimate the log-rank distribution, and it is consistent in a variety of simulated scenarios ( Supplementary Figure 1) . As expected, the most extreme statistics of the distribution were not observed due to random sub-sampling ( Supplementary Figure 2 ). This small caveat is not an issue because the estimated p values according to our procedure for these extreme statistic values would be, correctly, close to 0 and the observed statistics close to these extremes are accurately sampled ( Figure 2B , and Supplementary Figure 1B) .
To show the accuracy of the VALORATE procedure regarding the p-value estimations, we ran some simulations. The results show that when the assumption of a similar number of subjects in the two groups are met (n=100 subjects and n 1 =50 mutated), as in the ALRT, the p-values estimated by the ALRT and VALORATE are highly similar and highly correlated independently of the co-occurrence k ( Supplementary Figure 3) . However, when the number of subjects between groups becomes more dissimilar (n 1 = 30, 14, or 7) , the differences in p-value estimations turn higher, which correlates with changes in the symmetry and shape of the overall log-rank distribution. Moreover, the differences in p-value estimations also depend on the number of events co-occurring in the mutated risk group ( Supplementary Figure 3 ). For example, in an extreme case when n 1 =7 where the number of events in the mutated group was k=0 (so the 7 mutated samples are censored), the ALRT estimated a p-value of 0.15 whereas VALORATE estimated 1.8x10 -4 ( Supplementary Figure 4) . Contrary, in a case where k=1, the ALRT estimated a p-value of 3.5x10 -6 whereas VALORATE estimated 0.27. For these estimations, VALORATE used n 1 =7 estimated distributions L k , whereas the ALRT uses one χ 2 distribution.
The above results indicate that the VALORATE procedure can accurately (i) approximate the exact L distribution independent of the shape of the log-rank distribution and (ii) calculate the correct p-values since they converge to the ALRT when n 1 is similar to n/2. This proposes that VALORATE is superior to the ALRT for estimating the probability of the difference between two survival curves, especially in the cases where n 1 departs from n/2.
Then, we evaluated the precision of VALORATE on repeated runs across different values of sampling sizes from 10 3 to 10 6 . The results show that at ss=10,000, different runs are almost indistinguishable indicating high precision (Supplementary Figure 5 ). Even for ss=1,000, the shape of the distribution is highly similar to that in ss=1,000,000 showing that the procedure is consistent and robust. Nevertheless, at low sampling size, two runs may display slight differences. Although the differences in the estimation of the distribution and hence the p-values should be small, it is preferable to use larger sampling sizes to avoid small fluctuations between runs. Therefore, we used ss=100,000 for the cancer data analyses.
To evaluate VALORATE in cancer data including the estimation of p-values, we compared the calculations against those provided by ExaLT, which is based on three different approaches.
The results are highly similar between different methods and number of mutations ( Figure 2C) suggesting that the p-value estimations from VALORATE are also accurate in cancer data.
The computation time is an important issue because genomics data is being generated at high rates and typical analyses may involve estimations for the available stratifications (e.g. cancer sub-types, hormonal status, histological grades) and within systematic pipelines and data versions.
Thus, we assessed the running time for VALORATE and ExaLT changing the main parameter associated with accuracy. Even that both algorithms are different in essence, this test illustrates the time scale needed and how it grows. The Table 1 shows that VALORATE run more than 10,000 times faster than ExaLT. Besides, the running time of VALORATE does not grow drastically.
Comparison of detected gene mutations
met. Indeed, the differences in p-value estimations decrease for increasing number of mutations ( Supplementary Figure 7) . This indicates that, as the simulations suggested, the use of the ALRT estimation is progressively detrimental when decreasing the number of mutations on cancer data.
Identification of outcome associated driver mutations in cancer
The results shown above may have important implications in cancer genomics because it raises the possibility that other genes can be identified and that some of the previously identified genes using the ALRT could be suspicious. We, therefore, selected the most significant genes after correction by false discovery rate (FDR < 0.333). We observed large differences in the selected number of genes between VALORATE and the ALRT (Supplementary Figure 8A ). Only 7% of the genes was identified in both tests or 34% when considered the rank of top genes (Supplementary Figure 9 ). Two examples of such discrepancies are shown in Figure 4 for the genes RAB42 in breast cancer and LMTK2 in thyroid cancer. The gene RAB42 is the most significant reported by the TCGA in BRCA (p=1x10 -8 , q=9x10 -6 , http://firebrowse.org, doi:10.7908/C10Z72M8), however, in VALORATE the significance is marginal (p=0.02) and not selected after FDR correction (q=0.44).
Contrary, the LMTK2 in THCA, which is significantly mutated by frequency using MutSigCV 10 from TCGA but not associated with time to death using the ALRT (http://firebrowse.org, doi:10.7908/C1542N2H), is the most significant mutated gene using VALORATE (p=0.00026, q=0.075) . All these results suggest that VALORATE can identify genes that are missed by the ALRT and mark genes whose association with survival can be spurious, which contributes to providing important insights in cancer biology.
Nevertheless, we observed an apparent excess of significant mutations in uterine corpus endometrial carcinoma, bladder, and colon (China) (UCEC, BLCA, COCA-CN respectively) having more than 200 genes associated with survival according to VALORATE (Supplementary Figure 8A ).
The number of significant genes was weakly associated with dataset characteristics such as the number of samples, events, or censoring (Supplementary Figure 10 ). Instead, it was clearly associated with hypermutated samples (Supplementary Figure 11 ), which represent a minor proportion of samples with an exacerbated number of mutations 28 . This bias could not be observed using the ALRT in UCEC because there were no significant genes after FDR correction.
But in breast cancer (BRCA) where the ALRT detects many significant genes and VALORATE does not, the same issue arises using the ALRT (Supplementary Figure 11 ). This result proposes that hypermutated samples may bias the survival analyses of mutated genes. To explore this further, we re-analyzed all datasets removing the top 5% most mutated samples. The results show a substantial reduction of detected genes (Supplementary Figure 8B ) suggesting that indeed hypermutated samples influence the selection of many genes in several cancer types (except gliomas). Therefore, for further analysis, we used a refined criterion to remove hypermutated samples avoiding the removal of samples having few mutated genes (Supplementary Figure 12 and Materials and Methods).
Significant genes and risk assessment
After removing hypermutated samples and using an FDR=0.333, the ALRT calls 2,445 genes significant while VALORATE calls only 255 (Supplementary Figure 13 ). This decrease is similar across cancer types. Only in Gliomas, we observed 164 significant genes and the association was not related to hypermutated samples (Supplementary Figure 14) . From significant genes, 212 were detected in both tests ( Figure 5A ). Interestingly, the risk associated with genes between tests is different ( Figure 5B , chi-square test=2.2x10 -16 ). In the ALRT, only the 2% of identified genes are associated with low risk whereas in VALORATE low-risk genes reach 28%. We observed few but more low-risk gene mutations in cervical squamous cell carcinoma, esophageal carcinoma, glioblastoma, ovarian, stomach-esophagus cancers, thyroid cancer, uterine corpus endometrial cancer and few others (CESC, ESCA, GBM, OV, STES, THCA, and UCEC respectively, see Supplementary Figure 15 ). These findings may have implications in cancer biology because, apart from few exceptions such as IDH1 in gliomas, most coding mutations detected so far in cancer have been associated with decreasing survival rates using the ALRT 29 . Moreover, these results may also help to design low-risk biomarkers in other cancer types.
Significant genes across cancer types
It is expected that significant genes could be associated with survival in several cancer types because it is well known that some genes are broadly mutated such as TP53, PIK3CA, PTEN, KRAS, ARID1A 8 , and others (see www.tumorportal.org). Thus, we compared the significant genes detected by VALORATE across cancer types ( Figure 6 ). At FDR=0.333, only TP53 and MUC4 were found significantly associated with survival in at least two 'distinct' cancer types (TP53 to GBMLGG, LAML, BOCA-FR, BTCA-JP, PRAD-UK, and MUC4 to COCA-CN, KICH, and KIPAN). TP53 was marginally significant (FDR > .33 and p < 0.05) in many other cancer types and MUC4 in a few others. Interestingly, ATRX, well-known in glioblastomas 30 , was significant in gliomas, neuroblastoma, and pheochromocytoma/paraganglioma, all these related to nervous system. Some genes appear significant in one cancer type and marginally significant in others types.
Extreme cases are MUC16, MUC17, PCLO, and DNMT3A that are marginally significant in few more types. Some few genes appear significant in datasets that are composed of similar cancer types such as gliomas (GBMLGG, which is composed of glioblastoma and low-grade gliomas), stomachesophagus (STES), and kidney (KIPAN). Apart from these few exceptions, the majority of the genes seem cancer-type specific ( Figure 6 ) even when the significance assumption is relaxed ( Supplementary Figure 16 ). Remarkably, we did not observe significant survival association to other well-known cancer genes such as PIK3CA (lowest p=0.007, q=0.5 in UCEC), BRAF (lowest p=0.028, q=0.98 in KIRP), and FBXW7 (lowest p=0.018, q=0.99 in MELA-AU). From the 77 genes in Figure 6 , only 12 were also significant in the TCGA systematic analyses using the ALRT. Overall, these results suggest that association to survival is a different feature that mutation frequency supporting the exploration of association to a broader set of mutated genes rather than those detected by MutSigCV or similar methods.
Functional Validation of Significant Genes
In this study, 43 genes were significant only in VALORATE and can be considered novel associations ( Figure 6 ). In addition, many significant genes were highly ranked in VALORATE and obscured by its rank using the ALRT (Supplementary Figure 9 ). Therefore, we asked whether the significant genes may have plausible functional roles. For this, we made two tests regarding gene expression and functional impact of mutations. For the first, we reasoned that if a mutation in a coding gene is associated with survival, the gene should be expressed. The Figure 6 shows that most of the significant genes are expressed at some level. Some genes show expression levels around 15% (relative to their cancer) but the expression levels across tissues are highly consistent (for example TP53, MUC17, FLG2, TUBA3C) suggesting a common functional level of expression.
Moreover, the expression of mutated samples is highly similar to those observed in its cancer type.
We also tested the possible functional impact associated with the mutations of significant genes that may affect active sites, interactions with other proteins, and 3D folding. This can be corroborated comparing the non-synonymous mutations against conserved sequences in homolog proteins. For this, we used MutationAssesor 15 , which summarize the functional impact into neutral, low, medium, and high impact. We observed that the mutations in the identified genes have significantly higher impact categories than randomly chosen mutated genes from same cancer types and a similar number of mutations ( Supplementary Figure 17 ).
All these results suggest that, in general, coding mutations of the identified significant genes can be functional.
Discussion
A fundamental problem in cancer genomics and precision medicine is the determination of genomic alterations that could be associated with survival times. The selected alterations are then the seeds for research studies of biological mechanisms, drug discovery, and possible treatments.
The identification of the important genomic alterations is, however, challenging because most of the observed alterations are present in a low number of patients, there are thousands of alterations to test, and the associations need to be tested in several subject strata (grades, hormonal status, molecular subtypes, etc.). It has been recently shown that the statistical approximations used for this identification in cancer genomics are inaccurate 27 . The failure is basically due to the low number of patients presenting a specific alteration that generates heavily unbalanced population sizes. Although an accurate tool has been recently proposed 27 , it is prohibitively slow to compute in practice. In this work, we revisit the problem of estimation and propose, VALORATE, a novel estimation procedure that is independent of the number of alterations. We show by simulations that VALORATE is fast, precise, and accurate. In comparison with another method, VALORATE also provided accurate p-values in cancer data. We show that VALORATE is accurate when comparing largely unbalanced populations and highly similar to the ALRT when the populations are balanced. Thus, VALORATE can be used in both cases. This should facilitate its use and implementation in current bioinformatics pipelines (see Code section in Methods).
We demonstrate that the ALRT generates poor results under unbalanced populations. This agrees with previous results 26, 27 . Furthermore, our simulations demonstrate that the ALRT overestimates the significance for higher values of co-occurrences (k) and underestimates the significance for lower values of co-occurrences even in the same number of mutations (n 1 ). This could explain the large differences in genes called significant between the ALRT and VALORATE across cancer types.
Using VALORATE, we identified that hypermutated samples may bias the estimation of pvalues. This issue is related to two factors. First, VALORATE is a univariate procedure and suffers its same caveats, it tests the alterations in one gene (or locus) at the time being blind to other alterations. Second, the biology of the relation cancer-mutation-patient-survival is complex. In UCEC for example, hypermutated samples show high survival times and censored. Contrary, in BRCA, the hypermutated samples present poor survival. Here, we first removed top 5% most mutated samples to demonstrate the impact of the hypermutated samples. Then, we refined the criteria avoiding the unnecessary removal of samples to yield more fair estimations. Nevertheless, the decision whether to remove samples, how many, and which, deserves attention.
In datasets that are generated by the union of cancer types such as stomach-esophagus (STES), colorectal (COADREAD), pan-kidney (KIPAN) and others, we observed similar p-value estimations of the mutated genes in individual datasets compared to the merged datasets.
However, we observed 164 significant genes in gliomas (GBMLGG) while only 19 and 2 genes were significant in low-grade gliomas (LGG) and glioblastomas (GBM), respectively. This could be related to the fact that LGG shows higher survival than GBM, so genes that are more frequently mutated in LGG or GBM showing some degree of relation with survival would likely be significant in GBMLGG. Nevertheless, we noted that significant genes in GBMLGG are not necessarily significant or marginally significant in LGG or GBM (Supplementary Figure 18) . Thus, the significance in GBMLGG seems to be a reflect in gain of power given the aggregated number of samples. Surprisingly many cancer types do not show significant gene mutations. It is possible that the small sample size could affect some cancer datasets. For example, in Papillary thyroid carcinoma (THCA-SA), we analyzed only 15 samples. Nevertheless, in other cancers like breast, bladder, and skin cancer (BRCA, BLCA, and SKCM), no significant genes were found associated with survival time at FDR=0.333 even though that these datasets include more than 900, 400, and 340 samples respectively. This indicates that more focused analyses in different strata are needed in these cancer types. Another example is CLLE-ES where no genes significant were found using 218 patients, but some of the top ones (EGR2, ASXL1, NOTCH1, POT1, and NXF1) have been reported recently 31 using more than 450 patients. So it is likely that we are detecting fewer genes.
As a proof of concept, we focused in coding mutations, however, it is known that copy number alteration (CNA) are also related to survival 29, 31 . Thus, further analyses should focus also on CNA data. Some mutational biomarkers have been proposed for few cancer types 31 . In this context, we find that some genes previously identified using the ALRT may change its significance, that others may climb up in rank, that a considerable proportion of genes provides low-risk odds, and that hypermutated samples may influence the identification. These results suggest that novel or refined cancer biomarkers can be identified.
Based in our simulations and analysis in cancer data, we demonstrated that VALORATE is fast, precise, and accurate to estimate the p-value of the difference of two survival curves using the log-rank statistic even in cases when the number of subjects in survival groups are highly unbalanced. We conclude that VALORATE is a novel and useful tool in cancer genomics and other statistical analyses.
Methods
The VALORATE algorithm It is assumed that there are two groups of individuals and that for each patient we know their follow-up time and whether that time represent an event (e. g. death, metastasis, recurrence) or not (censored). n represents the total number of individuals and n 1 the individuals in the mutated group. There would be then r distinct ordered times and j=1..r represents each of these times. Let R j be individuals at risk that have not yet presented the event and R 1j those at risk for the mutated group. In each time j, there would be O j events (zero or more), and O 1j events for the mutated group. Under the null hypothesis of no difference between groups, O 1j is hypergeometric, so the expected number of events in the mutated group is E 1j =R 1j *O j /R j 25 . The log-rank statistic is then the sum of differences between the expected and the observed number of events 25 as
Under certain assumptions (high number of samples, not so few events, and similar group sizes 26 ), the mean of L is zero, and its variance is
Thus, a L 2 /V follows a c 2 distribution with one degree of freedom and this fact can be used to estimate the p-value of L being zero equivalent to no difference in the survival curves.
Nevertheless, the c 2 approximation yield bias estimations when n 1 << n/2 27 , which is the case in cancer genomics. To get accurate estimations of the probability of the two survival curves been equal when n 1 << n/2, we first rewrite the equation (1) 
where c j =1 is the indicator of event (death, recurrence, metastases) or c j =0 for censored observations (events not yet observed) ordered by time, x j =1 for subjects that are included in the mutated group or x j =0 for those who are not mutated, n is the total number of subjects, and n 1 , which is equal to ∑x j , is the total number of subjects mutated. To estimate the permuted density of the test statistic L, we rearranged equation (3) 
where it is evident that when n 1 << n/2, the Log-Rank statistic L, should depend strongly on the left term, k = % % 7 %)$ , the number of co-occurrences, which represent events (c j =1) that are also mutated (x j =1). The middle term also depends on x j but it is more robust to precise positions of x j =1 than the left term, which is highly dependent on the positions of x j =1. The right term, let be s 1 , is constant. From (4) it follows that k-s 1 < L < k for a particular value of k. This observation is important because it points out that the overall log-rank distribution can be seen as a mixture of distributions that depend on the number of co-occurrences k. The number of combinations for each co-occurrence k, although highly variable, can be easily calculated. To estimate a p-value, the relative proportion of combinations of the co-occurrences k is used to weight the relative contribution of the middle term to the overall distribution. Furthermore, the distribution of L conditional to a specific value of k (L k = P(L|k)) can be estimated by random sampling (permutations) instead of an non-conditioned all-combinations approach used by other methods sum of conditional distributions L k for specific values of k such as L= ∑w k L k . Where k varies from 0 to min(n 1 , d) and w k is the proportional contribution of the combinations for particular cooccurrences k. Finally, the probability of a specific observed statistic, L (gene) , is estimated by the area of the right (or left) fraction. The area is easily estimated summing the number of random samples of each L k that are greater (or lesser) than L (gene) multiplied by its corresponding weight w k .
Ties can be broken by random sampling the c vector in tie positions during the estimation of L k only in tie positions containing mixtures of events and censored observations. During the estimation of the p-value, we estimate the average log-rank statistic permuting tie positions.
The main parameter for VALORATE is the total number of samples (ss=sampling size) used for the estimation of the whole distribution. For each value of k, the sampling size ss k is obtained weighting ss respect to the probability of observing k (or a minimum of sampling, ss min , or all combinations if ss k is more than half of the number of combinations for k). We commonly use ss=100,000, and ss min =1,000. For each cancer dataset, this procedure was used to obtain L for each observed value of n 1 (usually for n 1 > 3 or n 1 =3 in special cases, see the next sections). The p-values have to be multiplied by a factor of 2 for two-tailed tests, which was used for comparisons with the ALRT.
Cancer mutation data
The mutation and clinical data were obtained from data portals. From TCGA (https://tcgadata.nci.nih.gov) specifically from the FireBrowse interface (http://firebrowse.org/) and from ICGC (https://dcc.icgc.org). A summary of the used data is shown in Supplementary 
Simulations of survival data and mutations
To determine the accuracy and precision of VALORATE, we performed simulations generating random c vectors for specific values of n, n 1 , and d. All possible values of L were calculated corresponding to all possible combinations of the x vector. Thus, the exact distribution of L was obtained and compared to the distribution estimated by VALORATE. 
Performance analyses
VALORATE analyses
For the simulations, the ss parameter used is specified in each particular experiment and ss min was 1,000 unless specified. For the cancer data analyses, we used ss=100,000. We focused on genes mutated in more than 4% of the patients. Thus, for 46 cancer datasets having 75 or more subjects with survival data, only genes mutated in 4 or more subjects were used. For the 15 cancer datasets having 74 or fewer subjects, only genes mutated in 3 or more subjects were used.
Selection of hypermutated samples
The range of mutation rates per cancer type is dependent on particularities of each cancer type 10 . For instance, the median of the number of mutated genes of neuroblastoma (NBL-US) and thymus cancer (THYM) are 1 and 9 respectively, while this number in bladder (BLCA) and melanoma (MELA-AU) is 169 and 343 ( Supplementary Figure 12) . Accordingly, to avoid removing samples in cancer types having few mutations, hypermutated samples were removed if they have more than 500 mutated genes, are within the top 5% of most mutated samples, and the number of mutated genes is larger than the median plus four times the median absolute deviation. The specific number of samples removed per cancer type is shown in Supplementary Figure 12 .
Functional analyses of mutated genes
To validate whether the significant genes obtained by VALORATE could have a functional effect, we performed two analyses. First, we reasoned that a significant gene will likely be expressed to exert a functional role. Thus, we obtained the gene expression levels from TCGA or ICGC data portals of available cohorts to assess the overall relative expression of the significant genes including the comparison between all subjects and those mutated. Microarray or RNA-Seq data was used ( Supplementary Table 1 ). Second, we thought that significant mutations should be more 'damaging' than random mutations. Therefore, we used MutationAssessor 15 to qualify the level of the functional impact of mutations. This tool classifies mutations according to evolutionary conservation patterns of affected amino acids in homolog proteins.
Code
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